Fig 1.
CONSORT flow diagram for single dose PK study of Cogni.Q pyranocoumarins.
Fig 2.
Chemical structures of pyranocoumarins, UHPLC characterization of test material Cogni.Q and example of UHPLC analysis of a plasma sample.
a) Structure of decursin (D), decursinol angelate (DA) and decursinol (DOH); b) Chemical fingerprinting of Cogni.Q and AGN extract by UHPLC-MS/MS in full scan mode (EMS scan); c) Typical chromatograms of D, DA and DOH in human plasma by UHPLC-MS/MS in MRM mode.
Table 1.
Baseline characteristics of healthy subjects and dosage information for decursin (D) and decursinol angelate (DA) normalized to body weight.
Fig 3.
Human plasma concentration (Cp)-time profiles of pyranocoumarins after a single oral dose of Cogni.Q.
(a) Parent compounds D and DA. (b) Product DOH. Mean ± SEM of all 20 subjects. Inserts show the semi-log plot of Cp versus time for corresponding analytes. Terminal t1/2 for D and DA was statistically the same (17.4 and 19.3 hours, respectively) and that for DOH was shorter (7.4 hours).
Table 2.
Key pharmacokinetic parameters of decursin (D), decursinol angelate (DA) and decursinol (DOH) in all human subjects (n = 20) receiving dietary supplement Cogni.Q orally vs. those in rats.
Fig 4.
Gender comparison of plasma concentration (Cp)-time profiles of pyranocoumarins after a single oral dose of Cogni.Q.
(a) DA. (b) DOH. Mean ± SEM. Men (n = 10) and women (n = 10).
Table 3.
Comparison of pharmacokinetic parameters of decursin (D), decursinol angelate (DA) and decursinol (DOH) in men vs. women receiving dietary supplement Cogni.Q orally.